Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
ID: 356611Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356611

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-294.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity through the Blueprint Neurotherapeutics Network (BPN) for Biologics, aimed at supporting biologic-based drug discovery and development for disorders of the nervous system. This initiative invites applications from U.S.-based small businesses to develop diverse therapeutic modalities, including antibodies and gene therapies, with a focus on specific nervous system disorders and a requirement for preliminary data demonstrating efficacy. The program emphasizes a phased, milestone-driven cooperative agreement, facilitating the transition of promising biotherapeutics from lead optimization to first-in-human trials while ensuring regulatory compliance and effective intellectual property management. Applications are due by January 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-294.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-294.html
    The Department of Health and Human Services announces the Blueprint Neurotherapeutics Network (BPN) for Biologics funding opportunity, emphasizing biologics-based drug discovery and development targeting the nervous and neuromuscular systems. This reissue, under activity code U44, invites applications from small business concerns to support diverse therapeutic modalities such as antibodies and gene therapies. The initiative includes a phased, milestone-driven cooperative agreement with NIH's assistance for industry-standard practices. Applicants must focus on specific nervous system disorders and present a compelling scientific rationale, including preliminary data demonstrating the efficacy of proposed agents. Eligible entities must be U.S.-based small businesses not exceeding 500 employees. The funding opportunity aims to accelerate the transition of promising biotherapeutics from lead optimization to first-in-human trials, with an emphasis on regulatory compliance and intellectual property management throughout the development process. Applications are due in January 2025, and interested parties are encouraged to consult NIH staff well in advance.
    Similar Opportunities
    Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System," aimed at supporting the development of biologic therapies for nervous and neuromuscular disorders. This initiative is structured as a cooperative agreement, divided into two phases: UG3 for lead optimization and UH3 for IND-enabling activities, with a focus on specific treatment applications for these disorders. The program encourages collaboration with NIH resources, including access to contract research organizations and experienced consultants, to facilitate the development of innovative therapies. Interested applicants, including higher education institutions and nonprofits, are encouraged to apply by August 18, 2027, and can find more information at the provided NIH grants link or contact NIH Grants Information at grantsinfo@nih.gov.
    Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) invites applications for the Blueprint Neurotherapeutics Network (BPN), aimed at supporting small businesses in advancing small molecule drug discovery and development for disorders of the nervous system. This funding opportunity, categorized as a Cooperative Agreement under the U44 Small Business Innovation Research (SBIR) program, encourages applicants to conduct disease-specific assays and collaborate with NIH-funded consultants and contract research organizations to facilitate the transition of promising drug candidates from discovery to clinical testing. The program emphasizes compliance with Good Laboratory and Clinical Practices, rigorous study designs, and diversity in research teams, making it a vital resource for small businesses lacking the necessary infrastructure for clinical development. Applications will be accepted starting January 9, 2024, with a closing date of August 19, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) for the Blueprint Neurotherapeutics Network (BPN), aimed at advancing biologic-based drug discovery and development for disorders of the nervous system. This initiative seeks applications from researchers focused on developing a variety of biotherapeutic modalities, including antibodies, peptides, proteins, oligonucleotides, gene therapies, and cell therapies, specifically targeting nervous system and neuromuscular disorders. The anticipated FOA is expected to be released in Fall 2024, with applications due in Winter 2025, and will utilize the UG3/UH3 activity code. Interested applicants should prepare for collaboration opportunities, as the estimated award date is set for December 1, 2025.
    Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) for the Blueprint Neurotherapeutics Network (BPN), focusing on biologic-based drug discovery and development for disorders of the nervous system. This initiative aims to solicit applications from researchers working on diverse biotherapeutic modalities, including antibodies, peptides, proteins, oligonucleotides, gene therapies, and cell therapies, to address various nervous system disorders. The anticipated FOA is expected to be released in Fall 2024, with applications due in Winter 2025, and will utilize the U44 activity code. Interested applicants should prepare for collaboration and project development, as the estimated award date is set for December 1, 2025. For further details, potential applicants can refer to the NIH website or contact the agency directly.
    Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity under the Blueprint Neurotherapeutics Network (BPN) for small molecule drug discovery and development targeting disorders of the nervous system. This initiative invites applications for cooperative agreements (UG3/UH3) from neuroscience investigators to advance their projects through various stages of drug development, including Discovery and Development phases, while collaborating with NIH-funded consultants and specialized contract research organizations (CROs). The program emphasizes the importance of innovative approaches to treating complex neurological conditions and requires adherence to Good Laboratory Practices (GLP) and Good Manufacturing Practices (GMP). Interested applicants can find more information and submit inquiries via the NIH Grants Information email at grantsinfo@nih.gov, with applications due by August 18, 2026.
    Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the Blueprint Neurotherapeutics Network (BPN) aimed at advancing small molecule drug discovery and development for disorders of the nervous system. This cooperative agreement invites applications from neuroscience researchers to conduct exploratory and developmental phases of drug development, allowing them to retain intellectual property rights while collaborating with NIH consultants and contract research organizations. The program is designed to facilitate the optimization and testing of drug candidates, adhering to regulatory standards and promoting diversity in research teams, ultimately seeking innovative therapeutic solutions for conditions aligned with NIH institutes such as NINDS, NIA, and NIMH. Interested applicants should prepare comprehensive applications, with key deadlines including a close date of August 18, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NeuroNEXT Small Business Innovation in Clinical Trials," aimed at encouraging small businesses to conduct exploratory clinical trials of investigational agents related to neurological disorders. This initiative seeks applications for Phase II Small Business Innovation Research (SBIR) projects, with a budget of up to $3 million over five years, focusing on trials that align with the strategic plan of the National Institute of Neurological Disorders and Stroke (NINDS). The program is designed to foster public-private partnerships to enhance the development and commercialization of innovative therapies, ultimately improving clinical outcomes in neuroscience research. Interested applicants must adhere to a Community Engagement and Research Inclusion (CERI) plan, with the first application deadline set for January 5, 2025, and additional deadlines throughout 2026 and 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)" aimed at supporting Small Business Concerns (SBCs) in conducting investigator-initiated exploratory clinical trials related to neurological disorders. This initiative encourages applications for Phase I and II studies focusing on drugs, biologics, devices, and therapies that align with the mission of the National Institute of Neurological Disorders and Stroke (NINDS), emphasizing the inclusion of a Plan for Enhancing Diverse Perspectives (PEDP) to foster innovation. The maximum funding amounts are $295,924 for Phase I and $1,972,828 for Phase II projects, with applications required to demonstrate readiness for eventual FDA regulatory approval. Interested applicants can begin submitting proposals on December 5, 2023, with the application deadline set for September 5, 2026; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders" (PAR-25-327), aimed at supporting Investigational New Drug (IND)-enabling studies and preparations for First-in-Human (FIH) clinical trials. This initiative focuses on advancing innovative gene-based therapies, such as oligonucleotides and viral vector approaches, for ultra-rare disorders affecting fewer than 6,000 patients, with an emphasis on projects that demonstrate robust proof of concept data and readiness for clinical trials. Eligible applicants include a wide range of organizations, including higher education institutions and various nonprofit and for-profit entities, with applications requiring detailed project planning and compliance with Good Manufacturing Practices (GMP). The application period opens on January 9, 2025, with a close date of October 8, 2027, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders," aimed at supporting the rigorous analytical validation of biomarker measurement methods for neurological diseases. This initiative seeks proposals from small businesses to conduct analytical validation, requiring applicants to justify their chosen biomarkers, outline contexts of use, and include a Plan for Enhancing Diverse Perspectives (PEDP) to foster inclusivity in research. Grants are available under U44 Small Business Innovation Research (SBIR) cooperative agreements, with funding amounts up to $700,000 annually for Phase I and up to $1.5 million for Phase II, and applications are due by June 25, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-098.html.